Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 2/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26209549 | 1.00 | KDM1A (0.34) | KDM1AGRIN1GRIN2BTRPV3FPR2 | |
| SCHEMBL5849019 | 1.00 | KDM1A (0.34) | KDM1AGRIN1GRIN2BTRPV3FPR2 | |
| SCHEMBL9631105 | 1.00 | KDM1A (0.34) | KDM1AGRIN1GRIN2BTRPV3FPR2 | |
| SCHEMBL12716045 | 0.96 | KDM1A (0.36) | KDM1AGRIN1GRIN2BTRPV3FPR2 | |
| SCHEMBL9405701 | 0.96 | KDM1A (0.36) | KDM1AGRIN1GRIN2BTRPV3FPR2 | |
| SCHEMBL9405698 | 0.96 | KDM1A (0.36) | KDM1AGRIN1GRIN2BTRPV3FPR2 | |
| SCHEMBL26209540 | 0.93 | KDM1A (0.38) | KDM1AFPR2HCRTR2 | |
| SCHEMBL26209563 | 0.93 | KDM1A (0.38) | KDM1AFPR2HCRTR2 | |
| SCHEMBL17827780 | 0.93 | KDM1A (0.38) | KDM1AFPR2HCRTR2 | |
| SCHEMBL17827785 | 0.93 | KDM1A (0.38) | KDM1AFPR2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1903090-B1 | Cyclohexene derivative having alkenyl, liquid crystal composition and liquid crystal display device | JNC CORP (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-7510749-B2 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1903090-A2 | Cyclohexene derivative having alkenyl, liquid crystal composition and liquid crystal display device | Chisso Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | POU2F2, HCN2, POU2F1 | KDM1A 1275/4885GRIN1 918/4885GRIN2B 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.